{"aliases":[{"type":"Synonym","name":"N26-(hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide"},{"type":"CodeName","name":"NN2211"},{"type":"USBrandName","name":"Victoza"},{"type":"CASRegistryName","name":"204656-20-2"}],"definition":{"html":"A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis.","text":"A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis."},"drugInfoSummaryLink":null,"nciConceptId":"C82239","nciConceptName":"Liraglutide","termId":775374,"name":"liraglutide","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"liraglutide"}